Long-term safety of aromatase inhibitors in the treatment of breast cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 189-204

  Nabholtz, Jean Marc A ^a  

^a Breast Cancer Research Institute La Prandie   (France)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Safety profile

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CHOLESTEROL; EXEMESTANE; FADROZOLE; FORMESTANE; HIGH DENSITY LIPOPROTEIN; LETROZOLE; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TAMOXIFEN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADVANCED CANCER; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; BLOOD PRESSURE; BONE DISEASE; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CANDIDIASIS; CARDIOTOXICITY; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FIBROMYALGIA; GASTROINTESTINAL TOXICITY; GYNECOLOGIC DISEASE; HEART FAILURE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROTOXICITY; NIGHT SWEAT; OSTEOARTHRITIS; OVERALL SURVIVAL; PAIN; PARESTHESIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SPINE FRACTURE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; UTERUS DISEASE; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VISUAL IMPAIRMENT; VOMITING; WRIST FRACTURE;

EID: 41549083745     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Agnelli G. 1997. Venous thromboembolism and cancer:a two-way clinical association. Thromb Haemost, 78:117-20.
2. Allred DC, Mohsin SK, Fuqua SA. 2001. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer, 8:47-61.
3. Andre F, Slimane K, Bachelot T, et al. 2004. Breast cancer with synchronous metastases:trends in survival during a 14-year period. J Clin Oncol, 22:3302-8.
4. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics. CA Cancer J Clin, 55:74-108.
5. ATAC Trialists' Group. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet, 359:2131-9.
6. ATAC Trialists' Group. 2003. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer, 98:1802-10.
7. ATAC Trialists' Group. 2005. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-2.
8. ATAC Trialists' Group. 2006. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:long-term safety analysis of the ATAC trial. Lancet Oncol, 7:633-43.
9. Atalay G, Dirix L, Biganzoli L, et al. 2004. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer:a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol, 15:211-7
10. Banerjee S, Smith IE, Folkerd L, et al. 2005. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol, 16:1632-8.
11. Beatson G. 1896. On the treatment of inoperable cases of carcinoma of the mamma:suggestions for a new method of treatment, with illustrative cases. Lancet, 2:104-7.
12. Bissett D, Davis JA, George WD. 1994. Gynaecological monitoring during tamoxifen therapy. Lancet, 344:1244-9.
13. Boccardo F, Rubagotti A, Puntoni M, et al. 2005a. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol, 23:5138-47.
14. Boccardo FM, Rubagotti A, Puntoni M, et al. 2005b. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol (Meeting Abstracts), 23:526.
15. Bolufer P, Ricart E, Lluch A et al. 1992. Aromatase activity and estradiol in human breast cancer:its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol, 10:438-46.
16. Bonneterre J, Thurlimann B, Robertson JF, et al. 2000. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post-menopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 18:3748-57.
17. Bonneterre J, Buzdar A, Nabholtz JM, et al. 2001. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer, 92:2247-58.
18. Buzdar AU, Robertson JF, Eiermann W, et al. 2002. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer, 95:2006-16.
19. Buzdar AU, on behalf of the ATAC Trialists' Group. 2006. Clinical features of joint symptoms observed in the 'Arimidex, Tamoxifen, Alone or in Combination' (ATAC trial. J Clin Oncol, 24(18s):551.
20. Cella D, Fallowfield L, Barker P, et al. 2006. Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of (years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat, 100:273-84.
21. Coates A, Keshaviah A, Thurlimann B et al. 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study BIG 1-98. J Clin Oncol, 25:486-92.
22. Colozza M, Cardoso F, Sotiriou C et al. 2005. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer, 6:61-76.
23. Coombes RC, Hall E, Gibson LJ et al. 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 350:1081-92.
24. Coombes RC, Kilburn LS, Snowdon C et al. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study):a randomized controlled trial. Lancet, 369-70.
25. Dewar J, Nabholtz J-MA, Bonneterre J, et al. 2000. The effect of anastrozole (Arimidex™) on serum lipids - data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat, 64 (Suppl):S51
26. [EBCTCG] Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365:1687-717.
27. Elisaf MS, Bairaktari ET, Nicolaides C, et al. 2001. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer, 37 (12):1510-3.
28. Endogenous Hormones and Breast Cancer Collaborative Group. 2002. Endogenous sex hormones and breast cancer in postmenopausal women:reanalysis of nine prospective studies. J Natl Cancer Inst, 94:606-16.
29. Engan T, Krane J, Johannessen DC, et al. 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat, 36:287-97.
30. Fallowfield LJ, Bliss JM, Porter LS, et al. 2006. Quality of life in the Intergroup Exemestane Study:a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol, 24:910-17.
31. Fisher B, Dignam J, Bryant J, et al. 1996. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst, 88:1529-42.
32. Fisher B, Jeong JH, Bryant J, et al. 2004. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, 364:858-68.
33. Geisler J, Haynes B, Anker G. 2002. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol, 20:751-7.
34. Gnant M, Jakesz R, Mlineritsch B et al. 2004. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat, 88:S8.
35. Gorodeski GI. 2002. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol, 16:329-55
36. Goss PE, Ingle JN, Martino S, et al. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 349:1793-802.
37. Goss PE, Ingle JN, Martino S, et al. 2005. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 97:1262-71.
38. Jakesz R, Jonat W, Gnant M, et al. 2005a. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366:455-62.
39. Jakesz R, Samonigg H, Greil R, et al. 2005b. Extended adjuvant treatment with anastrozole:Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol (Meeting Abstracts), 23:527.
40. Kataja V, Hietanen P, Joensuu H, et al. 2002. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study. Breast Cancer Res Treat, 76(Suppl 1):S156.
41. Levine MN. 1997. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost, 78:133-6.
42. Locker GY, Eastell R. 2003. The time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial. Proc Am Soc Clin Oncol, 22:25, abs 98.
43. McCloskey E, Eastell R, Lakner G, et al. 2005. Initial results from the LEAP study:the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenipausal women. San Antonio Breast Cancer Symposium, (abstr 2052)
44. Miller WR, Dixon JM. 2002. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control, 9 (2 Suppl):9-15.
45. Mouridsen H, Gershanovich M, Sun Y, et al. 2003. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol, 21:2101-9.
46. Nabholtz JM, Buzdar A, Pollak M, et al. 2000. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 18:3758-67.
47. Nabholtz JM, Bonneterre J, Buzdar A, et al. 2003. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:survival analysis and updated safety results. Eur J Cancer, 39:1684-9.
48. Nabholtz JM, Glogorov J. 2006. Cardiovascular safety profiles of aromatase inhibitors:a comparative review. Drug Saf, 29:785-801.
49. Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA Cancer J Clin, 55:74-108.
50. Paridaens R, Therasse P, Dirix L, et al. 2004. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. Proc ASCO, 23:abs 515.
51. Perez N, Borja J. 1992. Aromatase inhibitors:clinical pharmacology and therapeutic implications in breast cancer. J Int Med Res, 20:303-12.
52. Powles TJ, Hickish T, Kanis JA, et al. 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14:78-84.
53. Ring A, Dowsett M. 2004. Mechanisms of tamoxifen resistance. Endocr Relat Cancer, 11:643-58.
54. Rose C, Vtoraya O, Pluzanska A, et al. 2003. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer, 39:2318-27.
55. Rossouw JE, Anderson GL, Prentice RL, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288:321-33.
56. Samojlik E, Veldhuis JD, Wells SA, et al. 1980. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest, 65:602-12.
57. Saphner T, Tormey DC, Gray R. 1996. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol, 14:2738-46.
58. Schmid M, Jakesz R, Samonigg H, et al. 2003. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease:Austrian breast and colorectal cancer study group trial 6. J Clin Oncol, 21:984-90.
59. Schmitt M, Kuhn W, Harbeck N, et al. 1999. Thrombophilic state in breast cancer. Semin Thromb Hemost, 25:157-66
60. Segaloff A, Weeth JB, Meyer KK, et al. 1962. Hormonal therapy in cancer of the breast. 19. Effect of oral administration of delta- 1 -testolactoneon clinical course and hormonal excretion. Cancer, 15:633-5.
61. Wasan KM, Goss P, Pritchard P, et al. 2005. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol, 16:707-15.
62. Whelan TJ, Goss PE, Ingle JN, et al. 2005. Assessment of quality of life in MA 17:a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol, 23:6931-40.
63. Winer EP, Hudis C, Burstein HJ, et al. 2005. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer:status report 2004. J Clin Oncol, 23:619-29.
64. Wiseman LR, McTavish D. 1993. Formestane. A review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs, 45:66-84.
65. Wojtacki J, Lesniewski-Kmak K, Pawlak W, et al. 2004. Anastrozole therapy and lipid profile:an update. Eur J Cancer, 2:142
66. Wojtacki J, Lesniewski-Kmak K. 2005. Biochemical markers of the risk for cardiovascular disease in women with early breast cancer treated with anastrozole. Eur J Cancer, 3:105
67. Wysowski DK, Honig S, Beitz J. 2002. Uterine sarcoma associated with tamoxifen use. N Engl J Med, 346:1832-3.